Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
all their news has proven to be bull shit imho.....notice everytime they put out bs this garbage crashes......
etrade or td ameritrade wont let you buy this garbage ,,,company nothing but a crooked scam ....
the news was more con job bullshit.... you cant buy this through etrade they wont let you buy this worthless shit.....
etrade wont let you buy this crap.
folks call this number they putout news yesterday ,,,more bull crap.
Jim DiPrima YOU will see its more bull crap ...its some bs life alert system ..DONT BELIEVE CALL IT.
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
PAOG is working with Veristat, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82103
> Dow Jones Newswires
April 28, 2021 12:13 ET (16:13 GMT)
KALY has gross profit margins at 95%. I'm holding my shares.
more new more bullshit lies....this company is crooked .....you cant even buy it with most brokers....etrade or td ameritrade .
$kaly $0.00205 v -0.00005 (-2.38%)
Volume: 1,599,299 @03/19/21 3:49:51 PM EDT
Company garbage go to their website the still have not updated the phone number... and they never will. These pricks belong in prison every time they put out news its just bull crap the pps never does crap ... this company do your dd if not you will get pucked over 3 years of bull chit ....email them call them if you want a good laugh sad but so true .....call them its some bull chit ..... never ever will return or calllsor emails... dont believe try it you will see..
Is it true Ferri left and took RxResp...
with him to PAOG? Is it true KALI shareholders were to get divys from PAOG in exchange? Is it true those divys never showed?
The last Diprima (PAOG) scam involved RBII taking all of PAOGs clinics, while giving PAOG a "new CEO" who turned out to not be CEO at all; just a place holder for DiPrima. In other words, PAOG got nothing while DiPrima and RBII got all the clinics.
you can only sell this crap on etrade and td ameritrade you cant buy it...
company nothing but a crooked scam dont believe do your dd,,,call these crooks email these crooks.....
these folks need to be in prison
Whateve's KALY is the most green in my portfolio today already...
correct this company full of bull chit lies call the number if you want a good laugh so sad but so true kaly crooked as puck
Totally crooked. Been watching this for 2 years and always someone says how crooked they are. Won’t touch this ever. Be warned.
$kaly $0.0029 v -0.0001 (-3.33%)
Volume: 9,248,226 @02/19/21 3:53:52 PM EST
i just want these pricks to go to jail .....
I agree with you but here I am stuck with a few shares. Are you still in it all? Whats your exit number? Thanks
here kaly inc crooked number call leave a message ....they wont call you back....all departments are busy too funny ...its an answering service....
folks their crooked as hell. 1-214-210 -0459 call leave a message its as dirty and crooked as they come.
its in china crooked piece of crap
Frederick Ferri
Chief Executive Officer, Kali Inc
CURRENT POSITION
Chief Executive Officer, Kali Inc
TENURE AT CURRENT POSITION
12/2018-PRESENT
PREVIOUS POSITION
--
EDUCATION
--
BOARD MEMBERSHIPS
--
INDUSTRY
Financial Services
CURRENT PRICE
KALY:US0.00USD+-0.00-32.50%AS OF 12:02 PM EST 02/18/2021SEE QUOTE
Career History
TITLE
COMPANY
TENURE
Chief Executive Officer
Kali Inc
12/2018–PRESENT
CEO/Founder
NCM Biotech
PRESENT
About Kali Inc
Kali, Inc. operates as a holding company. The Company, through its subsidiaries, invests in companies.
SECTOR
Financials
INDUSTRY
Financial Services
SUB-INDUSTRY
Asset Management
FOUNDED
10/30/2006
ADDRESS
Xiamen Guanyin Shan Intl Bldg Center, 5F, 151 Taidong Road Xiamen, 361008 China
Dark/Defunct company with Caveat Emptor warning from OTC Markets.
No wonder reputable trading platforms ban KALY trading.
SEC delisting C.E. stocks. Not looking good.
this is their last bull chit pr call the number on the bottom you will be shocked about this piece of chit..
dont believe call the number ..its for some bull chit medical alert device you wear around your neck ...what a pucking scam
PAOG Targets $18 Billion Anxiety And Depression Treatment Market
9:07 AM ET 2/11/21 | Dow Jones
Sandusky, Ohio--(Newsfile Corp. - February 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company's recently announced CBD nutraceutical development expansion will target the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025.
The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach.
The presentation is scheduled to be published next week on Tuesday, Feb 16(th) .
Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
In addition to PAOG's ongoing efforts to develop a pharmaceutical treatment for COPD, the company has announced engaging with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
PAOG plans to establish a revenue stream this year from its nutraceuticals' initiative adding to its recently confirmed a $300,000 sales agreement executed by the company's cannabis cultivation subsidiary acquired last year from Puration, Inc. (OTC Pink: PURA). PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.
PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/74248
> Dow Jones Newswires
February 11, 2021 09:07 ET (14:07 GMT)
ITS BEEN NOTHING BUT A SELL OFF THIS COMPANY HAS NOTHING ...WHY HAVENT THEY SHUT THIS FREAKING FRAUD DOWN.
GO TO THE RECENT PRS AND LOOK AT THE BOTTOM CAL THE NUMBER IF YOU WANT TO REAL HERE SOME BULL CHIT .....AGAIN CALL THE NUMBER YOU WILL SEE..
PEOPLE ARE DUMPING JUST TO TRY TO GET SOME MONEY BACK.
TD AMERITRADE AND ETRADE WONT LET YOU BUY THIS CHIT ...I HAVE AN ACCOUNT WITH BOTH....
THESE PUCKERS NEED TO GO TO PRISON NOW ....AGAIN SEE FOR YOURSELF CALL THE BULL CHIT NUMBER .... IT WILL PISS YOU OFF HAS NOTHING TO DO WITH KALY BULL BULL CHIT...
KALY Up 13.89% Today, quite a few Big up days lately !!
No information for months, 2 press releases within hour asking for partners and then we sold to paog with no money/terms discussed?
This is shady as it gets, but what do we have to lose at this point.
I don't trust any of this, slowly selling my portion as we go up.
Dark/Defunct company with Caveat Emptor warning from OTC Markets.
No wonder reputable trading platforms ban KALY trading.
SEC delisting C.E. stocks. Not looking good.
Maybe PAOG is buying back your shares cheap. Then you get no dividend.Heck i do not know what is moving this,who else would buy it?
Reddit/Robinhood gangs are shorting USMJ, but cannot attack KALY because KALY is traded under grey sheet and not pink. Most if not all Reddit/Robinhood traders cannot trade grey sheet tickers.
KALY is being protected by being under grey trading platform and can not be shorted by Reddit/Robinhood gangs. It is kind of like "a blessing in disguise"
etrade wont let you buy it try again,,,,stop the lies.
Opening transactions for Caveat Emptor securities are not permitted because of the risks associated with trading shares in these companies.
NSDQ
KALY KALI INC COM
refreshRefresh quote
Symbol
KALY
Last Price x Size / Exch info_outline
0.0047
x 100000U +0.0006 (+14.39%)
Bid x size
0.0046 x 50000
Ask x size
0.0047 x 601938
Volume
13.00M
There was more sell volume today than total volume for the last 2 days...
But there was also more buy volume than total volume for the last two days...
As you all know volume precedes price.
Strap in. I've been on a hot streak lately, lets see if this continues my streak or ends it...lol...
I used TD Ameritrade (not for much longer) and I had no issue buying KALY
Instafills.
QEDN on the other hand orders rejected...I have it at .0006
Saying you can't buy KALY with TDA is a bald faced lie.
KALY Up 28.12% Today. All You Need To Know !!!
How do we upload images?
feel free too posts your buys ...
I bought ... KALY
you can only sell you cant buy i have both etrade and td
Um yeah u can, I'm holding on TD
you can not buy this through td ameritrade or etrade....
KALY huge DIP ... add here !!!
#cannabis $ KALI
imo
KALY Up Another 56.25% So Far ... What Is Going On ???
KALY Up Another 28% Today . 3 Bigly Up Days with BIG Volume in the Last 4 Days !!
Where is the PAOG stock ?
I bought this because of their COPD fix trials in 2018 at $0.00676 but they sold the cure method rights to PURA. Just wondering what KALY is doing now as I find so very little information that don't even look for it anymore but I am long and strong as my operating method so I still have it hoping for a break. Again, why are they worth anything or have any good future?
Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."
Wow , someone has been loading since .001 for a reason!
Something is happening!!
GO KALY
Followers
|
315
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
32923
|
Created
|
01/26/09
|
Type
|
Free
|
Moderators |
GOLDMAN SMALL CAP RESEARCH REPORT AUTHORIZED: 5,000,000,000 OUTSTANDING: 1,276,240,706 RESTRICTED: 255,174,312 UNRESTRICTED: 1,021,066,394
KALI'S NEW BUSINESS PLAN With the patented intellectual property (IP), to include the existing and ongoing research and development acquired from NCM Biotech, Kali will now concentrate on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain as a symptom of various diagnoses. Kali will also concentrate on the development of health and wellness therapies. The cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029. The cannabis concentrates for wellness, edibles, and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022. Prior to the acquisition by Kali, NCM Biotech was engaged with a number of different universities on a number of separate research initiatives. As an example, and as a preview of an upcoming announcement, NCM has been involved in an ongoing study with a university in Kentucky on the use of a cannabis therapy derived from Kali’s patented extraction process for the treatment of Chronic Obstructive Pulmonary Disease (COPD). A paper on the results of the study using Kali’s patented extraction process is anticipated to be published soon. NCM Biotech's medical advisory team includes John N. Gaitanis, MD., Director of Child Neurology at Tufts Medical Center/Floating Hospital for Children; Lloyd R. Saberski, M.D., Associate Professor of Anesthesiology and Chronic Pain Management, Yale University, and John McMichael, Ph.D., President & CEO Beech Tree Labs. Preclinical Research Study Results on Therapy for Respiratory Disease (COPD and Asthma) Below is a link to research recently conducted by Professor Jeffrey Osborn, President of Biomedical Science Research Group, LLC, and Biology Professor at the University of Kentucky Final Report for Pilot Study - NCMB-1 (aka Blue Dream)
LETTER TO SHAREHOLDERS FROM INCOMING CEO FREDERICK FERRI - NOVEMBER 27, 2018 Dear Kali Shareholders – |
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |